314 related articles for article (PubMed ID: 32023483)
1. Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.
Liu X; Simon JM; Xie H; Hu L; Wang J; Zurlo G; Fan C; Ptacek TS; Herring L; Tan X; Li M; Baldwin AS; Kim WY; Wu T; Kirschner MW; Gong K; Zhang Q
Mol Cell; 2020 Mar; 77(6):1294-1306.e5. PubMed ID: 32023483
[TBL] [Abstract][Full Text] [Related]
2. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
3. Prolyl Hydroxylase 3 Knockdown Accelerates
Zacharias NM; Wang L; Maity T; Li L; Millward SW; Karam JA; Wood CG; Navai N
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799686
[TBL] [Abstract][Full Text] [Related]
4. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
5. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
6. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
Zhou L; Yang H
PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
[TBL] [Abstract][Full Text] [Related]
7. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
8. Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma.
Guo K; Wei Y; Wang Z; Zhang X; Zhang X; Liu X; Wu W; Wu Z; Zhang L; Cui CP
Cell Death Dis; 2022 Feb; 13(2):97. PubMed ID: 35110537
[TBL] [Abstract][Full Text] [Related]
9. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
10. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
11. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.
Razafinjatovo C; Bihr S; Mischo A; Vogl U; Schmidinger M; Moch H; Schraml P
BMC Cancer; 2016 Aug; 16():638. PubMed ID: 27530247
[TBL] [Abstract][Full Text] [Related]
12. A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.
Salama MF; Carroll B; Adada M; Pulkoski-Gross M; Hannun YA; Obeid LM
FASEB J; 2015 Jul; 29(7):2803-13. PubMed ID: 25805832
[TBL] [Abstract][Full Text] [Related]
13. A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization.
Nowicka AM; Häuselmann I; Borsig L; Bolduan S; Schindler M; Schraml P; Heikenwalder M; Moch H
Oncogene; 2016 Jun; 35(24):3125-38. PubMed ID: 26500060
[TBL] [Abstract][Full Text] [Related]
14. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
15. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.
Yi Y; Mikhaylova O; Mamedova A; Bastola P; Biesiada J; Alshaikh E; Levin L; Sheridan RM; Meller J; Czyzyk-Krzeska MF
Clin Cancer Res; 2010 Nov; 16(21):5142-52. PubMed ID: 20978146
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
[TBL] [Abstract][Full Text] [Related]
17. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
Zhang J; Wu T; Simon J; Takada M; Saito R; Fan C; Liu XD; Jonasch E; Xie L; Chen X; Yao X; Teh BT; Tan P; Zheng X; Li M; Lawrence C; Fan J; Geng J; Liu X; Hu L; Wang J; Liao C; Hong K; Zurlo G; Parker JS; Auman JT; Perou CM; Rathmell WK; Kim WY; Kirschner MW; Kaelin WG; Baldwin AS; Zhang Q
Science; 2018 Jul; 361(6399):290-295. PubMed ID: 30026228
[TBL] [Abstract][Full Text] [Related]
18. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
19. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
[TBL] [Abstract][Full Text] [Related]
20. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]